Aim7 30/15/500mg Tablet XR 15s

Aim7 30/15/500mg Tablet XR 15s is a triple-combination oral antidiabetic medicine designed to address multiple metabolic defects responsible for high blood sugar in type 2 diabetes.

Metformin works by reducing glucose production in the liver and improving insulin sensitivity in muscles, thereby lowering fasting blood sugar levels. Gliclazide stimulates the pancreas to release insulin in response to rising blood sugar, particularly after meals, helping control postprandial glucose spikes. Pioglitazone enhances insulin sensitivity in fat tissue, muscle, and liver cells, allowing glucose to be utilised more effectively by the body.

By combining these complementary mechanisms, Aim7 30/15/500mg Tablet XR 15s helps control both fasting and post-meal blood sugar levels. It is commonly prescribed for patients whose diabetes remains poorly controlled on monotherapy or dual therapy, or for those already stabilised on these medicines separately.

This medicine should always be taken under medical supervision, along with dietary control, regular exercise, and periodic monitoring of blood glucose, kidney function, and liver health. Your doctor will determine the appropriate dose based on your clinical condition and treatment response.

When used as directed, Aim7 30/15/500mg Tablet XR 15s provides a convenient and effective option for long-term glycaemic control and may help reduce the risk of diabetes-related complications.

Aim7 30/15/500mg Tablet XR 15s is indicated for the management of type 2 diabetes mellitus in adults.

Type 2 Diabetes Mellitus

Helps control elevated blood sugar levels in adults with insulin resistance and reduced insulin secretion.

Inadequate Control with Monotherapy or Dual Therapy

Prescribed when diet, exercise, and one or two oral antidiabetic medicines fail to maintain target glucose levels.

Fasting and Postprandial Blood Sugar Control

Addresses both baseline and after-meal blood glucose through complementary actions.

Reduction of Long-Term Diabetes Complications

Improved glycaemic control may reduce the risk of heart disease, kidney damage, nerve damage, and vision problems.

Triple-Action Glycaemic Control

Targets insulin secretion, insulin sensitivity, and hepatic glucose production simultaneously.

Improved Insulin Effectiveness

Enhances the body’s response to insulin at the cellular level.

Post-Meal Sugar Regulation

Gliclazide helps limit sharp increases in blood sugar after meals.

Reduction in Fasting Blood Sugar

Metformin and Pioglitazone work together to lower baseline glucose levels.

Long-Term HbA1c Improvement

Supports sustained average blood sugar control over time.

Convenient Combination Therapy

Reduces pill burden and may improve treatment adherence.

Like all medicines, Aim7 30/15/500mg Tablet XR 15s may cause side effects, although not everyone experiences them.

Common Side Effects

• Nausea, vomiting, diarrhoea, or abdominal discomfort

• Low blood sugar (hypoglycaemia), especially if meals are delayed or skipped

• Weight gain or mild fluid retention

• Headache or dizziness

• Metallic taste in the mouth

Uncommon Side Effects

• Ankle or foot swelling

• Joint or muscle pain

• Skin rash or itching

• Changes in appetite

Serious Side Effects (Seek Immediate Medical Attention)

• Severe Hypoglycaemia: Confusion, loss of consciousness, excessive sweating, tremors.

• Lactic Acidosis: Severe tiredness, muscle pain, breathing difficulty, stomach pain.

• Heart Failure Worsening: Rapid weight gain, breathlessness, swelling of legs.

• Liver Injury: Yellowing of skin or eyes, dark urine, persistent nausea.

Aim7 30/15/500mg Tablet XR 15s should be taken exactly as prescribed by your doctor. It is usually taken once or twice daily with meals to reduce stomach irritation and minimise the risk of low blood sugar.

Swallow the tablet whole with water. Do not crush, chew, or break it unless advised. Taking it at the same time each day helps maintain steady blood sugar levels.

Regular follow-up is essential to monitor blood glucose, kidney function, liver enzymes, and overall response to therapy.

Aim7 30/15/500mg Tablet XR 15s helps control blood sugar levels in adults with type 2 diabetes by acting on three complementary pathways involved in glucose regulation, providing balanced and sustained glycaemic control.

• Insulin Secretion Stimulation (Gliclazide): Gliclazide stimulates the pancreatic beta cells to release insulin when blood sugar levels rise, particularly after meals, helping reduce postprandial glucose spikes.

• Hepatic Glucose Reduction and Insulin Sensitisation (Metformin): Metformin lowers blood sugar by reducing excess glucose production by the liver and improving insulin sensitivity in muscle tissue, which helps lower fasting blood glucose levels.

• Enhanced Peripheral Insulin Sensitivity (Pioglitazone): Pioglitazone improves the body’s response to insulin in fat, muscle, and liver cells, allowing glucose to move more efficiently from the bloodstream into cells.

By simultaneously improving insulin secretion, insulin sensitivity, and glucose regulation, Aim7 30/15/500mg Tablet XR 15s supports control of both fasting and post-meal blood sugar levels and contributes to long-term HbA1c reduction when combined with lifestyle measures.

• Meal Regularity: Maintain regular meal timings to reduce the risk of hypoglycaemia, particularly due to the Gliclazide component.

• Weight and Swelling Monitoring: Monitor body weight and ankle swelling regularly, as Pioglitazone may cause fluid retention in some patients.

• Hypoglycaemia Preparedness: Carry a fast-acting source of glucose such as sugar tablets or sweets to manage sudden low blood sugar symptoms.

• Routine Follow-Up: Attend regular medical check-ups and blood tests to monitor blood sugar, liver function, and kidney health during treatment.

• Alcohol (Moderate): Increases the risk of hypoglycaemia and may raise the likelihood of Metformin-associated Lactic Acidosis.

• High-Carbohydrate Diet (Mild): May reduce overall blood sugar control despite medication use.

• Insulin or Other Sulfonylureas (Moderate): May increase the risk of hypoglycaemia and require dose adjustment.

• Diuretics (Moderate): May increase the risk of dehydration, fluid imbalance, or blood pressure changes.

• Corticosteroids (Moderate): Can raise blood sugar levels and reduce the effectiveness of diabetes control.

• Iodinated Contrast Media (Severe): Metformin should be temporarily discontinued before contrast-based imaging procedures to prevent kidney-related complications.

• Heart Failure (Severe): Pioglitazone may worsen fluid retention and is generally avoided in patients with moderate to severe heart failure.

• Severe Liver Disease (Severe): Not recommended due to an increased risk of liver-related adverse effects.

• Renal Impairment (Moderate): Reduced kidney function increases the risk of Metformin accumulation and requires close monitoring.

If you miss a dose, take it as soon as you remember with food. If it is almost time for your next dose, skip the missed one and continue your regular schedule. Do not take two doses at the same time.